Recent U.S. IPO activity features selective issuance amid elevated Treasury yields near 5.3% and geopolitical pressures, with 83 traditional offerings raising over $120 billion through September 2026—well above prior-year totals excluding outliers like SpaceX. Smaller biotechs and SPACs continue to price weekly, supported by a deepening pipeline in AI infrastructure, energy, and technology, while larger candidates such as Anthropic target mid-November listings and others shift into 2027 due to valuation discipline and market volatility. Hong Kong proceeds have already exceeded historical nine-month records, signaling sustained global risk appetite. Key near-term catalysts include fourth-quarter economic data releases, potential FOMC communications, and earnings from recent listings that could influence broader sentiment into year-end.